Viz.ai, a San Francisco, CA-based leading AI-powered disease detection and care coordination platform, announced that it raised a $100 million Series D funding round at a $1.2 billion valuation.
The round was led by Tiger Global and Insight Partners, with participation from early backers including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
The new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz Platform to detect and triage additional diseases, and grow its customer base globally.
Company: Viz.ai, Inc.
Round: Series D
Funding Month: April 2022
Lead Investors: Tiger Global and Insight Partners
Additional Investors: Scale Ventures, Kleiner Perkins, Threshold, GV, Sozo Ventures, CRV, and Susa
Company Website: https://www.viz.ai/
Software Category: AI-powered Disease Detection and Care Coordination Platform
About the Company: Viz.ai, located in San Francisco, Tel Aviv, Portugal, and Amsterdam, pioneered the use of AI algorithms and machine learning to increase the speed of diagnosis and care for a variety of acute and emergent diseases across hospitals and health systems. The Viz Platform is a transformative, intelligent care coordination solution that unifies synchronized care collaboration, high fidelity mobile image viewing, automated workflows, and improved visibility at decision-making moments. Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,000 hospitals in the US and EMEA. Viz.ai’s life science portfolio expands the power of the AI-powered Viz Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently. The company was named to the Forbes 2021 Next Billion-Dollar Startups list of the 25 fastest-growing venture-backed startups and has been on the Forbes AI 50 list for three consecutive years.